St. Joseph's Healthcare Hamilton

Summary

St. Joseph's Healthcare Hamilton is a medical facility located in HAMILTON, Ontario. This center is recognized for care of Lung Cancer, Central Venous Access Device Thrombosis, Blood Clot, Kidney Failure, Idiopathic Pulmonary Fibrosis and other specialties. St. Joseph's Healthcare Hamilton is involved with conducting 297 clinical trials across 429 conditions. There are 30 research doctors associated with this hospital, such as Moin Khan, MD, Deborah Cook, MD, Bobby Shayegan, MD, and Harsha Shanthanna, MD.

Top PIs

Clinical Trials running at St. Joseph's Healthcare Hamilton

Lung Cancer

Asthma

Atrial Fibrillation

Prostate Cancer

Cardiovascular Disease

Interstitial Lung Disease

Bipolar Disorder

Bladder Cancer

Atrial Flutter

Chronic Obstructive Pulmonary Disease

NIR Fluorescence-Guided Surgery

for Early Stage Lung Cancer

Lungs are made up of individual lobes. When a lung cancer tumour is detected in one of these lobes, surgeons typically perform a Lobectomy. A Lobectomy is the surgery most commonly done to treat early-stage lung cancer and requires removal of an entire lobe of the lung, which removes a large amount of lung tissue For patients with small tumours saving as much healthy lung tissue as possible is important. Each lobe of the lung has smaller sections called segments. When a lung cancer is in one of these segments, it is possible to remove that segment, without removing the entire lobe. This surgery is called a segmentectomy. Compared to a lobectomy, a segmentectomy saves a larger amount of healthy lung tissue. With the advances in screening technology for lung cancer tumours, an increasing amount of very small lung cancer tumours are being found, and the demand for segmentectomy is increasing. A segmentectomy is a hard surgery to perform robotically because it is difficult to view the tissue lines that separate each segment within the lobe. As a result, it is difficult for the surgeon to see exactly which pieces of tissue should be removed. Because of these challenges, many patients having robotic surgery will have a lobectomy, even if a full lobectomy is not needed. Near-Infrared Fluorescence (NIF) using indocyanine green (ICG) fluorescent dye is a recent advancement in the robotic platform of robotic surgery. The surgeon will view the CT scan to determine which segment the tumour is located in. Once identified, the surgeon will isolate the segment by cutting off the blood supply to that segment. Then ICG will be injected into a vein. It is expected that the entire lung, except the isolated segment, which will remain 'dark' as it was isolated from blood supply, will fluoresce, giving off a green hue when viewed with the da Vinci Firefly camera. The surgeon will identify 'dark' segment, and will remove it. A pathologist will examine the excised tissue to ensure that the tumour was removed in its entirety. Once confirmed, the surgeon will end the procedure. If the pathologist determines that the segment removed did not contain the entire tumour, then the surgeon will perform a routine lobectomy. This ensures patient safety and confirms that all participants will have the entire tumour removed from their lung.

Recruiting

2 awards

Phase 1

4 criteria

Synapse 3D + IC-Green

for Early-Stage Lung Cancer

This trial tests a new method for lung cancer surgery that uses 3D planning and special dye to help surgeons remove only the diseased part of the lung. It aims to help patients keep more of their healthy lung tissue, especially those with early-stage cancer or other health problems.

Recruiting

1 award

Phase 1 & 2

3 criteria

Liquid Biopsies and Exhaled VOC

for Lung Cancer

The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for detecting mutations in extracted cell-free DNA in non-small cell lung cancer (NSCLC) patients, before and after surgery, and any recurrence within a 24-month postoperative follow-up period. This is a pilot feasibility study, proposed as a 24-month prospective, single-center, non-interventional, observational trial with NSCLC-adenocarcinoma patients indicated for resection surgery with curative intent.

Recruiting

1 award

N/A

3 criteria